Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

Introduction

This page provides a comprehensive analysis of the known insider trading history of Cline Christopher R.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Cline Christopher R. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TVTX / Travere Therapeutics, Inc. CHIEF FINANCIAL OFFICER 92,083
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Cline Christopher R.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases TVTX / Travere Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TVTX / Travere Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TVTX / Travere Therapeutics, Inc. Insider Trades
Insider Sales TVTX / Travere Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TVTX / Travere Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-09-03 TVTX Cline Christopher R. 454 18.2000 454 18.2000 8,263 0 19.6100 641 7.76
2025-05-05 TVTX Cline Christopher R. 1,784 21.0500 1,784 21.0500 37,553
2025-04-11 TVTX Cline Christopher R. 48 13.1446 48 13.1446 631
2025-02-03 TVTX Cline Christopher R. 5,192 20.1200 5,192 20.1200 104,463
2025-01-22 TVTX Cline Christopher R. 865 18.9409 865 18.9409 16,384
2024-09-09 TVTX Cline Christopher R. 2,490 11.5200 2,490 11.5200 28,685
2024-09-04 TVTX Cline Christopher R. 514 9.5093 514 9.5093 4,888
2024-04-11 TVTX Cline Christopher R. 54 6.7400 54 6.7400 364
2024-02-01 TVTX Cline Christopher R. 3,818 8.5313 3,818 8.5313 32,573
2024-01-23 TVTX Cline Christopher R. 853 9.0684 853 9.0684 7,735
2023-09-05 TVTX Cline Christopher R. 457 14.7102 457 14.7102 6,723
2023-05-10 TVTX Cline Christopher R. 455 16.5900 455 16.5900 7,548
2023-04-11 TVTX Cline Christopher R. 47 21.4900 47 21.4900 1,010
2023-02-01 TVTX Cline Christopher R. 1,588 21.7520 1,588 21.7520 34,542
2023-01-24 TVTX Cline Christopher R. 852 21.9044 852 21.9044 18,663

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TVTX / Travere Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Cline Christopher R. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-09-05 2025-09-04 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale X -119 92,083 -0.13 19.71 -2,345 1,814,956
2025-09-05 2025-09-03 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -454 92,202 -0.49 18.20 -8,263 1,678,076
2025-08-28 2025-08-27 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale X -470 92,656 -0.50 17.31 -8,136 1,603,875
2025-05-05 2025-05-05 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -1,784 93,126 -1.88 21.05 -37,553 1,960,302
2025-05-05 2025-05-02 4 TVTX Travere Therapeutics, Inc.
Common Stock
M - Exercise 4,920 94,910 5.47
2025-04-14 2025-04-11 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -48 89,990 -0.05 13.14 -631 1,182,883
2025-02-04 2025-02-03 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -5,192 90,038 -5.45 20.12 -104,463 1,811,565
2025-02-04 2025-01-31 4 TVTX Travere Therapeutics, Inc.
Common Stock
A - Award 21,500 95,230 29.16
2025-01-23 2025-01-22 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -865 73,730 -1.16 18.94 -16,384 1,396,513
2024-09-09 2024-09-09 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -2,490 74,595 -3.23 11.52 -28,685 859,334
2024-09-09 2024-09-05 4 TVTX Travere Therapeutics, Inc.
Common Stock
A - Award 6,750 77,085 9.60
2024-09-05 2024-09-04 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -514 70,335 -0.73 9.51 -4,888 668,837
2024-04-12 2024-04-11 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -54 70,849 -0.08 6.74 -364 477,522
2024-02-02 2024-02-01 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -3,818 70,903 -5.11 8.53 -32,573 604,895
2024-02-02 2024-01-31 4 TVTX Travere Therapeutics, Inc.
Common Stock
A - Award 25,000 74,721 50.28
2024-01-25 2024-01-23 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -853 49,721 -1.69 9.07 -7,735 450,890
2023-09-05 2023-09-05 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -457 50,574 -0.90 14.71 -6,723 743,954
2023-05-12 2023-05-10 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -455 51,031 -0.88 16.59 -7,548 846,604
2023-04-13 2023-04-11 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -47 51,486 -0.09 21.49 -1,010 1,106,434
2023-02-02 2023-02-01 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -1,588 51,533 -2.99 21.75 -34,542 1,120,946
2023-02-02 2023-01-31 4 TVTX Travere Therapeutics, Inc.
Common Stock
A - Award 20,250 53,121 61.60
2023-01-26 2023-01-24 4 TVTX Travere Therapeutics, Inc.
Common Stock
S - Sale -852 32,871 -2.53 21.90 -18,663 720,020
2022-09-01 3 TVTX Travere Therapeutics, Inc.
Common Stock
28,723
2022-09-01 2022-09-01 4 TVTX Travere Therapeutics, Inc.
Common Stock
A - Award 5,000 33,723 17.41
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)